SULT2B1 and Obesity: SULT2B1 was previously known to decrease serum and hepatic lipid levels by deactivating the oxysteroid-derivative endogenous LXR agonists (14), and inhibit gluconeogenesis by targeting HNF4α (15), both of which may have contributed to the alleviation of metabolic abnormalities in obesity.